CZECRIN - Czech Clinical Research Infrastructure Network Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2019
NCT04554485
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

CZECRIN - Czech Clinical Research Infrastructure Network

Active Ingredients

Drugs in Phase 2 Trials (2)

blinatumomab (blincyto) (1 trial)

ponatinib (iclusig) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2